Biocryst Pharmaceuticals (BCRX) Equity Ratio (2010 - 2026)

Biocryst Pharmaceuticals has reported Equity Ratio for 17 years, with the latest figure at 1.19 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 26.5% year-over-year to 1.19; the trailing twelve-month figure through Mar 2026 stood at 1.19 (down 26.5% YoY), and the FY2025 full-year result was 0.23, up 76.12% from the prior year.
• Equity Ratio for Q1 2026 stood at 1.19, down from 0.23 in the prior quarter.
• The five-year high for Equity Ratio was 0.23 in Q4 2025, with the low at 1.19 in Q1 2026.
• Historically, Equity Ratio has averaged 0.76 across 5 years, with a median of 0.87 in 2025.
• Annual changes were most pronounced in 2022 — Equity Ratio slumped 194.46% — and 2025, when it soared 76.12%.
• Biocryst Pharmaceuticals' Equity Ratio stood at 0.54 in 2022, then sank by 64.51% to 0.88 in 2023, then dropped by 10.13% to 0.97 in 2024, then soared by 76.12% to 0.23 in 2025, then plunged by 413.9% to 1.19 in 2026.
• The last three Equity Ratio figures came in at 1.19 (Q1 2026), 0.23 (Q4 2025), and 0.87 (Q3 2025), per Business Quant data.